The Estée Lauder Companies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EL research report →
Range $80 – $111
Price Chart
About the company
The Estée Lauder Companies Inc. is a global entity dedicated to the development, marketing, and sale of a diverse range of premium beauty and personal care items worldwide. Its extensive product catalog encompasses numerous offerings across four primary categories.
- CEO
- Stephane de la Faverie
- IPO
- 1995
- Employees
- 44,460
- HQ
- New York City, NY, US
AI snapshot
Six angles, distilled from the data.
The stock is in a recovery phase after a long drawdown, trading back above its 50-day average but still below the 200-day line. That leaves the setup constructive but not fully repaired, with the shares still well under the 52-week high and closer to the middle of the annual range than the lows.
Street sentiment is mixed-to-cautious, with a Hold consensus and an average target of 91.92 versus a 90 median. Recent calls have mostly nudged targets higher, including Jefferies to 88, TD Cowen to 90, Barclays to 80, and UBS to 86, but the rating mix still leans neutral.
The next print carries a favorable beat backdrop, with EL beating in 7 of the last 7 reported quarters. Analysts expect EPS to improve to 3.19 next year from a negative TTM EPS base, so shareholders should watch whether margin recovery and demand trends keep the rebound on track.
No discretionary insider buying or selling stands out. The recent filings are dominated by award grants to directors and executives, which are routine compensation-related flows rather than conviction trades.
Profitability is still uneven, but the core economics remain solid: gross margin is 74.7% and operating margin is 14.93%. Revenue grew 4.6% year over year, while EPS growth remains negative at -45.5%, showing the recovery is more visible in sales than in bottom-line earnings.
EL still screens as a premium consumer staples name, with a 39.9 P/E and a consensus target near 91.92. The setup favors a quality brand portfolio and strong gross margins, but the market is still discounting the earnings reset and leverage burden versus steadier peers.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.69B
- P/E
- -128.84
- Fwd P/E
- 27.50
- PEG
- 15.59
- P/S
- 2.14
- P/B
- 7.96
- EV/EBITDA
- 28.21
- Div Yield
- 1.60%
- Gross Margin
- 73.40%
- Op Margin
- 7.56%
- Net Margin
- -1.67%
- ROE
- -6.29%
- ROIC
- -11.17%
Latest fiscal year · YoY change
- Revenue
- $14.29B-8.5%
- Gross Profit
- $10.56B-5.6%
- Op Income
- $958.00M
- Net Income
- $-1,133,000,000-390.5%
- EPS
- $-3.15-389.0%
- OCF Growth
- -46.1%
- FCF Growth
- -53.5%
- 52W High
- $121.64
- 52W Low
- $66.22
- 50D MA
- $83.98
- 200D MA
- $91.83
- Beta
- 1.25
- RSI (14)
- 59
- Avg Volume
- 3.16M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Estée Lauder said fiscal Q3 momentum continued, with 2% organic sales growth, 40% EPS growth, and higher full-year and preliminary fiscal 2027 margin outlooks.· May 1, 2026
- Organic sales rose 2% in Q3, led by double-digit fragrance growth and continued strength in Mainland China and priority emerging markets.
- EPS grew 40% to $0.91, while operating margin expanded 360 basis points to 15% on gross margin and cost leverage.
- Full-year fiscal 2026 guidance was raised to about 3% organic sales growth, 10.7% to 11% operating margin, and $2.35 to $2.45 EPS.
- Management’s preliminary fiscal 2027 view calls for 3% to 5% organic sales growth and 12.5% to 13% operating margin.
- The company highlighted Beauty Reimagined, One ELC, and PRGP restructuring as key drivers, while still citing Middle East disruption and North America brick-and-mortar pressure as headwinds.
In fiscal Q3, organic net sales increased 2% year over year; gross margin was 76.4%, up 140 basis points; operating margin was 15.0%, up from 11.4%; and diluted EPS was $0.91 versus $0.65 last year, a 40% increase. For the first 9 months, operating cash flow was $1.2 billion versus $671 million a year ago, and CapEx was $306 million, down 23%. For fiscal 2026, the company now expects organic net sales growth of approximately 3%, gross margin of about 75%, operating margin of 10.7% to 11%, and diluted EPS of $2.35 to $2.45, with Middle East disruption expected to have less than a 1% impact for the full year. For Q4, management expects an unfavorable impact of about 2 percentage points to sales growth and $0.06 to EPS from Middle East disruption. For fiscal 2027, preliminary guidance is for 3% to 5% organic sales growth and 12.5% to 13.0% operating margin.
Stephane de la Faverie framed the quarter as evidence that Beauty Reimagined is working, saying the company is back to organic growth and expanding margins for the first time in four years. He pointed to broad-based gains across regions, stronger online performance, and share gains in key markets like China and the U.S. His tone was confident and ambitious, emphasizing that One ELC, channel rebalancing, innovation, and PRGP are building a more leveraged P&L and that margin recovery is a milestone, not a sprint.
Akhil Shrivastava focused on the numbers behind the margin expansion and cash generation. He said gross margin reached 76.4% in Q3, helped by PRGP benefits and lower excess and obsolescence, and operating margin reached 15.0% as nonconsumer-facing expenses fell 4% and consumer-facing investment rose 9%. He also noted $1.2 billion in operating cash flow for the first 9 months, $306 million of CapEx, and total cumulative restructuring charges of $1.1 billion through March 31, with total restructuring charges now expected to be $1.5 billion to $1.7 billion before taxes.
Analysts focused on whether the company can sustain margin expansion beyond fiscal 2027, how much growth is needed to support the margin target, and whether more channel exits like department stores are coming. Management said the margin opportunity remains substantial because of gross margin improvement, SG&A efficiencies, restructuring savings, and One ELC/technology/media transformation, and it did not rule out further channel resizing in lower-productivity doors. On North America and travel retail, management said the U.S. can return to growth next year, inventories are in good shape, and the Beijing/Shanghai duty-free issue was less severe than feared, with travel retail showing low-single-digit growth and Hainan retail sales up over 30%.
The call suggested that multiple levers are working at once: organic growth returned, margins are expanding, cash flow improved materially, and management raised both fiscal 2026 and preliminary fiscal 2027 targets. The company also cited share gains in China, the U.S., online, and travel retail, plus a richer innovation pipeline and continued channel expansion into Amazon, TikTok Shop, Sephora, and other growth channels.
The company still faces pressure from North American brick-and-mortar weakness, retailer bankruptcies, shop-in-shop closures, and softness for some brands. Management also flagged uncertainty from the Middle East conflict, evolving tariffs and macro volatility, and said full fiscal 2027 guidance is still preliminary, with more detail to come in August.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 361.67M
- Float Shares
- 359.94M
of shares held by institutions
901 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Michael McCaulHouse · TX10 | Buy | Apr 1, 26 | Filing → |
| Michael McCaulHouse · TX10 | Buy | Apr 9, 26 | Filing → |
| Michael McCaulHouse · TX10 | Buy | Apr 8, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Michael McCaulHouse · TX10 | Sell | Sep 30, 25 | Filing → |
| Dan NewhouseHouse · WA04 | Sell | Apr 11, 25 | Filing → |
| Sheldon WhitehouseSenate · RI | Sell | Apr 29, 25 | Filing → |
| Sheldon WhitehouseSenate · RI | Sell | Apr 29, 25 | Filing → |
| Michael McCaulHouse · TX10 | Buy | Mar 5, 25 | Filing → |
| Michael McCaulHouse · TX10 | Buy | Mar 4, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Feb 12, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Jan 15, 25 | Filing → |
| Kevin HernHouse · OK01 | Sell | Dec 31, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 27.95M | ▲ 1.04M |
| Blackrock, Inc. | 20.83M | ▲ 2.28M |
| Fmr LLC | 18.11M | ▲ 1.77M |
| Vanguard Capital Management LLC | 16.07M | ▲ 16.07M |
| Bank Of America Corp | 13.84M | ▲ 12.53M |
| State Street Corp | 11.54M | ▼ 250.69K |
| Schroder Investment Management Group | 8.02M | ▼ 121.99K |
| Eagle Capital Management LLC | 7.93M | ▼ 796.93K |
| Geode Capital Management, LLC | 6.66M | ▲ 8.54K |
| Independent Franchise Partners Llp | 6.63M | ▼ 1.21M |
| Bank Of New York Mellon Corp | 5.82M | ▼ 973.59K |
| Invesco Ltd. | 5.21M | ▼ 1.37M |
Held by 1,622 ETFs
Biggest fund positions in EL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 21, 26 | FRIBOURG PAUL J | other | 409.73 |
| Jul 21, 26 | STERNLICHT BARRY S | other | 327.78 |
| Jul 21, 26 | Zinterhofer Eric Louis | other | 327.78 |
| Jun 15, 26 | Zinterhofer Eric Louis | other | 10.9 |
| Jun 15, 26 | Zinterhofer Eric Louis | other | 7.69 |
| Jun 15, 26 | ZANNINO RICHARD F | other | 41.44 |
| Jun 15, 26 | ZANNINO RICHARD F | other | 11.6 |
| Jun 15, 26 | Tejada Jennifer | other | 17.08 |
| Jun 15, 26 | Strong Dana | other | 3.06 |
| Jun 15, 26 | STERNLICHT BARRY S | other | 184.38 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EL coverage
Recent articles, reports, and earnings notes.

Estee Lauder (EL): Recovery Story With Leverage Risk
Estee Lauder is showing early signs of a turnaround, with fragrance, online sales, and Mainland China improving. But heavy debt, negative earnings, and restructuring costs keep this a Hold.

Estée Lauder doesn’t need a deal if the turnaround is finally real
Estée Lauder's failed Puig talks look like a positive, not a setback. With M&A noise gone, the market can focus on a turnaround that is finally showing up in margins, China trends, and repeated earnings beats.

The Estée Lauder Companies Inc. (EL) climbs 11.7% after talks end
The Estée Lauder Companies Inc. (EL) climbs sharply after hours after ending merger talks with Puig, removing a major uncertainty from the stock. The move is backed by stronger recent earnings, improved margins, and rising analyst targets, shifting focus back to EL’s standalone turnaround story.
Want a deeper read on EL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
EL Stock to Post Q4 Earnings: Here's What Investors Should Know
zacks.com · Aug 13
Estee Lauder (EL) Earnings Expected to Grow: Should You Buy?
zacks.com · Aug 12
The Estée Lauder Companies to Webcast Discussion of Fiscal 2026 Fourth Quarter and Full-Year Results on August 19, 2026
businesswire.com · Aug 5
5 Top-Ranked Stocks to Buy Ahead of Potential Earnings Beats
zacks.com · Aug 3
Bank of America Corp DE Has $993.57 Million Holdings in The Estee Lauder Companies Inc. $EL
defenseworld.net · Aug 1
EL CIERRE – 31 DE JULIO
youtube.com · Jul 31
Did The Estee Lauder Companies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Jul 29
Estee Lauder (EL) Just Reclaimed the 50-Day Moving Average
zacks.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed August 7, 2026 · Live quote · Not investment advice